Oligodendroglioma natural history, complications, and prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma natural history, complications, and prognosis On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma natural history, complications, and prognosis |
|
FDA on Oligodendroglioma natural history, complications, and prognosis |
|
CDC on Oligodendroglioma natural history, complications, and prognosis |
|
Oligodendroglioma natural history, complications, and prognosis in the news |
|
Blogs on Oligodendroglioma natural history, complications, and prognosis |
Overview
Natural history
Complications
Prognosis
Oligodendrogliomas are generally felt to be incurable using current treatments. However compared to the more common astrocytomas, they are slowly growing with prolonged survival. In one series, median survival times for oligodendrogliomas were 11.6 years for grade II and 3.5 years for grade III.[1]
Long-term survival is reported in a minority of patients.[2] With aggressive treatment and close monitoring, it is possible to outlive the typical life expectancies for both low grade and high grade oligodendrogliomas. In rare cases, patients have survived for up to fifteen years post-diagnosis. Westergaard’s study (1997) showed that patients younger than 20 years had a median survival of 17.5 years.[3] Another study shows a 34% survival rate after 20 years. [4]
1p/19q deletion has been correlated with both chemosensitivity and improved prognosis in oligodendrogliomas.[5][6]
A recent study showed that the presence of the 1p19q codeletion is a relevant marker of longer overall survival in patients with low grade gliomas and isocitrate dehydrogenase 1 (IDH1) mutation 3. In other words: Radiopaedia
IDH1 positive + 1p19q codeletion = better prognosis IDH1 positive + no 1p19q codeletion = shorter overall survival
References
- ↑ Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89. PMID: 15977639
- ↑ Tatter SB. Recurrent malignant glioma in adults. Curr Treat Options Oncol. 2002 Dec;3(6):509-24. PMID: 12392640,
- ↑ Herbert H. Engelhard, M.D., Ph.D., Ana Stelea, M.D., and Arno Mundt, M.D.[1] p.449
- ↑ Feigenberg SJ, Amdur RJ, Morris CG, Mendenhall WM, Marcus RB, Friedman WA (2003). "Oligodendroglioma: does deferring treatment compromise outcome?". Am. J. Clin. Oncol. 26 (3): e60–6. doi:10.1097/01.COC.0000072507.25834.D6. PMID 12796617.
- ↑ Laigle-Donadey F, Benouaich-Amiel A, Hoang-Xuan K, Sanson M (2005). "[Molecular biology of oligodendroglial tumors]". Neuro-Chirurgie (in French). 51 (3-4 Pt 2): 260–8. PMID 16292170.
- ↑ Walker C, Haylock B, Husband D; et al. (2006). "Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors". Neurology. 66 (11): 1661–7. doi:10.1212/01.wnl.0000218270.12495.9a. PMID 16769937.